2023/07/04 16:48:44 | |
---|---|
Price | |
9.74 EUR | |
Difference | 4.06% (0.38) |
ISIN | US09077D2099 |
Symbol | BFRI |
Exchange | Frankfurt |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 6 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 9.04 EUR |
High | 9.74 EUR |
Low | 9.04 EUR |
Close (prev. day) | 9.36 EUR |
VWAP | 9.74 EUR |
Volume (pcs) | 2 |
Trading volume | 15.58 |
Number of trades | 2 |
Last size | 2 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/08/12 |
![]() |
Global Equity Ratings |
![]() |
2024/07/24 |
![]() |
Global Equity Ratings |
![]() |
2024/07/12 |
![]() |
Global Equity Ratings |
![]() |
2024/06/21 |
![]() |
Global Equity Ratings |
![]() |
2024/06/14 |
![]() |
Global Equity Ratings |
![]() |
2023/07/04 16:48:44 | |
---|---|
Price | |
9.74 EUR | |
Difference | 4.06% (0.38) |
ISIN | US09077D2099 |
Symbol | BFRI |
Exchange | Frankfurt |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 6 EUR |
Benchmark | S&P 500 |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | 9.04 EUR |
High | 9.74 EUR |
Low | 9.04 EUR |
Close (prev. day) | 9.36 EUR |
VWAP | 9.74 EUR |
Volume (pcs) | 2 |
Trading volume | 15.58 |
Number of trades | 2 |
Last size | 2 |
6m | 1Y | 3Y | |
Perf (%) | -38.74% | -71.35% | - |
Perf (abs.) | -6.16 | -24.26 | - |
Beta | 1.17 | -0.11 | 1.07 |
Volatility | 103.85 | 91.66 | 101.09 |
Ø price 5 days | Ø volume 5 days (pcs.) | 9.30 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 8.70 EUR (5) |
Ø price 100 days | Ø volume 100 days (pcs.) | 10.99 EUR (4) |
Ø price 250 days | Ø volume 250 days (pcs.) | 17.59 EUR (3) |
YTD High | date | 18.40 EUR (2023/01/10) |
YTD Low | date | 7.26 EUR (2023/06/16) |
52 Weeks High | date | 40.80 EUR (2022/07/14) |
52 Weeks Low | date | 7.26 EUR (2023/06/16) |
BIOFRONTERA INC. |
- - |
120 Presidnetial Way, Suite 330 - 01801 Woburn |
Telefon: +1-781-245-1325 |
Fax: + |
E-mail: info-us@biofrontera.com |
Biofrontera, Inc. is a biopharmaceutical company, which engages in the commercialization of pharmaceutical products. It specializes in the treatment of dermatological conditions, caused primarily by exposure to sunlight that results in sun damage to the skin. The company is focused on the treatment of actinic keratosis and markets a topical antibiotic for treatment of impetigo. Its products include Ameluz and Xepi, its two prescription drugs, and BF-RhodoLED, a lamp used with Ameluz, for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company was founded on March 3, 2015 and is headquartered in Woburn, MA. |
Beth Hoffman | Member of Board of Directors |
Heikki Lanckriet | Member of Board of Directors |
John Borer | Member of Board of Directors |
Kevin Weber | Member of Board of Directors |
Dr. Hermann Lübbert | Chairman of Managing Board |
Fred Leffler | Member of Executive Committee |
Any information, material and services regarding financial instruments and securities provided by Erste Group Bank AG or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites”) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions (the “Interested Party“).
The publication and distribution of information as well as offering and selling of products and services described on the Websites is prohibited by law in some jurisdictions. For this reason, persons in countries in which the publication as well as the offering and selling of products and services described on the Websites are not permitted by law, must not enter the Websites and/or acquire the products displayed on the Websites.
Neither Erste Group nor any third party shall offer access to the Websites or offer the products to especially, but not limited to citizen/residents of the United States and “U.S. person” (as defined in Regulation S under the US Securities Act 1933 as amended), citizen/resident of Australia, Canada, Great Britain and Japan. For this reason, the distribution or redistribution of the information, materials and products into United States, Australia, Canada, Great Britain and Japan or into any other jurisdiction where it is not permitted under the applicable law, as well as to the citizens/residents of these countries shall be prohibited.
The securities displayed on the Websites have not been and will not be registered under the US Securities Act of 1933 and trading in the securities has not been approved for purposes of the US Commodities Exchange Act of 1936. For this reason the securities may, inter alia, not be offered, sold or delivered within the United States or, for the account and benefit of U.S. persons.
The Interested Party is solely responsible to examine, whether he may enter the Websites under the law applicable to it. Erste Group shall not be responsible for the distribution of content of any of the Websites to individuals or entities which provide false information about their right to enter the Websites. For this reason Erste Group shall not be liable for any legal claims or damages which may result from the unauthorized entering or reading of the Websites.
By agreeing to this hereto, the Interested Party confirms that
(i) It has read, understood and accepted this Information and the Disclaimer;
(ii) It informed itself about any possible legal restriction and warrants that it is not restricted or prohibited to enter the Websites according to any law applicable; and
(iii) It does not make available the contents of the Websites to any person who is not qualified by law to enter the Websites.
(iV) It is no consumer.